QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)

Century Therapeutics (IPSC) Stock Forecast, Price & News

$2.03
-0.07 (-3.33%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.00
$2.16
50-Day Range
$2.03
$3.23
52-Week Range
$2.00
$11.95
Volume
97,568 shs
Average Volume
134,653 shs
Market Capitalization
$121.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33

Century Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
655.3% Upside
$15.33 Price Target
Short Interest
Healthy
2.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.87mentions of Century Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.02) to ($1.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

357th out of 964 stocks

Biological Products, Except Diagnostic Industry

54th out of 159 stocks


IPSC stock logo

About Century Therapeutics (NASDAQ:IPSC) Stock

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

IPSC Price History

IPSC Stock News Headlines

Century Therapeutics Inc.
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Analyst Ratings for Century Therapeutics
See More Headlines
Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IPSC Company Calendar

Last Earnings
8/09/2023
Today
9/26/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IPSC
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.33
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+651.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-130,930,000.00
Net Margins
-2,782.34%
Pretax Margin
-2,733.81%

Debt

Sales & Book Value

Annual Sales
$5.20 million
Book Value
$5.13 per share

Miscellaneous

Free Float
55,223,000
Market Cap
$121.91 million
Optionable
Not Optionable
Beta
0.66
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Michael C. Diem M.D. (Age 52)
    Chief Financial Officer
    Comp: $650.66k
  • Dr. Adrienne Farid Ph.D. (Age 61)
    COO & Head of Early Devel.
    Comp: $650.66k
  • Dr. Gregory Russotti Ph.D. (Age 56)
    Interim Pres & CEO
  • Mr. Kenneth J. Dow J.D.
    Sr. VP of Gen. Counsel
  • Dr. Shane Williams Ph.D.
    Chief People Officer
  • Dr. Hyam I. Levitsky M.D. (Age 65)
    Pres of R&D
  • Michael Naso Ph.D.
    Sr. VP of Cell Engineering
  • Mr. Douglas Carr CPA
    Sr. VP of Fin. & Operations and Sec.













IPSC Stock - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IPSC shares.
View IPSC analyst ratings
or view top-rated stocks.

What is Century Therapeutics' stock price forecast for 2023?

8 Wall Street research analysts have issued 1-year price targets for Century Therapeutics' stock. Their IPSC share price forecasts range from $5.00 to $28.00. On average, they predict the company's stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 651.6% from the stock's current price.
View analysts price targets for IPSC
or view top-rated stocks among Wall Street analysts.

How have IPSC shares performed in 2023?

Century Therapeutics' stock was trading at $5.13 at the beginning of the year. Since then, IPSC stock has decreased by 60.2% and is now trading at $2.04.
View the best growth stocks for 2023 here
.

Are investors shorting Century Therapeutics?

Century Therapeutics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 642,200 shares, a drop of 14.0% from the August 15th total of 747,100 shares. Based on an average daily trading volume, of 100,600 shares, the days-to-cover ratio is currently 6.4 days. Approximately 2.7% of the company's shares are sold short.
View Century Therapeutics' Short Interest
.

When is Century Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our IPSC earnings forecast
.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.02. The firm earned $0.10 million during the quarter, compared to analyst estimates of $1.54 million. Century Therapeutics had a negative net margin of 2,782.34% and a negative trailing twelve-month return on equity of 43.88%.

When did Century Therapeutics IPO?

(IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

What is Century Therapeutics' stock symbol?

Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC."

Who are Century Therapeutics' major shareholders?

Century Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.71%), State Street Corp (0.76%), Geode Capital Management LLC (0.74%), Northern Trust Corp (0.30%), Charles Schwab Investment Management Inc. (0.27%) and New York Life Investment Management LLC (0.20%). Insiders that own company stock include Eli Casdin, Luis Borges and Versant Venture Capital Vi, L.
View institutional ownership trends
.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Century Therapeutics' stock price today?

One share of IPSC stock can currently be purchased for approximately $2.04.

How much money does Century Therapeutics make?

Century Therapeutics (NASDAQ:IPSC) has a market capitalization of $121.91 million and generates $5.20 million in revenue each year. The company earns $-130,930,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How many employees does Century Therapeutics have?

The company employs 163 workers across the globe.

How can I contact Century Therapeutics?

The official website for the company is www.centurytx.com. The company can be reached via phone at 267-817-5790 or via email at investor.relations@centurytx.com.

This page (NASDAQ:IPSC) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -